EHRA Premium Access

MANIFEST-PF: multi-national survey on methods, efficacy and safety on the post-approval clinical use of pulsed field ablation

Congress Session

7 more presentations in this session

Sex differences in early rhythm control therapy in atrial fibrillation

Thumbnail

Sex differences in early rhythm control therapy in atrial fibrillation - discussion.

Thumbnail

MANIFEST-PF - discussion.

Thumbnail

High radiofrequency power for faster and safer pulmonary vein ablation trial (POWER FAST III)

Thumbnail

POWER FAST III - discussion.

Thumbnail

Access the full session

Late Breaking Clinical Trials II - atrial fibrillation, news on ablation and sex differences

Thumbnail

About the event

Image

EHRA 2022

3 April - 5 April 2022

Sessions Presentations

Related content

EHRA Premium Access

Biophysical parameters and time to isolation of pulmonary veins with a novel cryoballoon: results of POLAR ICE study

3 April 2022

EHRA Premium Access

Pulsed field ablation of atrial fibrillation: recurrence rate after first pulmonary vein isolation and first insights into durability at redo procedures

3 April 2022

EHRA Premium Access

Selective epicardial pulsed field ablation of atrial ganglionated plexi causes anti-arrhythmic prolongation of refractoriness: demonstration of feasibility in cardiac surgery patients

3 April 2022

This platform is supported by

logo Novo Nordisk